Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5342413 | 0.93 | ALDH1A1 (0.51) | ALDH1A1HPGDPTPN11TSHRPLA2G2D | |
| SCHEMBL5360481 | 0.92 | ALDH1A1 (0.56) | ALDH1A1HPGDPTPN11TSHRPLA2G2D | |
| SCHEMBL12431891 | 0.85 | ALDH1A1 (0.48) | KMT2AALDH1A1HPGDCREBBPPTPN11 | |
| SCHEMBL5397525 | 0.84 | NCEH1 (0.48) | KMT2AALDH1A1HPGDCREBBPNCEH1 | |
| SCHEMBL5693936 | 0.81 | CA12 (0.57) | KMT2AALDH1A1NCEH1TSHR | |
| SCHEMBL38656246 | 0.81 | CA12 (0.57) | KMT2AALDH1A1NCEH1TSHR | |
| SCHEMBL9341996 | 0.80 | MRGPRX4 (0.57) | KMT2AHPGDTP53 | |
| SCHEMBL177169 | 0.80 | THRA (0.56) | KMT2AALDH1A1HPGDCREBBPPTPN11 | |
| SCHEMBL3918327 | 0.79 | TSHR (0.59) | ALDH1A1NCEH1TSHR | |
| SCHEMBL12433142 | 0.79 | MAPT (0.47) | KMT2AALDH1A1HPGDNCEH1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846366-B1 | NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-7718703-B2 | Norvaline derivative and method for preparation thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7718703-B2 | Norvaline derivative and method for preparation thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-7186448-B2 | Composition and method for temporarily fixing solid | JSR CORPORATION (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20060275939-A1 | Composition and method for temporarily fixing solids | JSR CORPORATION (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1522567-A1 | COMPOSITION AND METHOD FOR TEMPORARILY FIXING SOLID | JSR Corporation (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20040185187-A1 | Composition and method for temporarily fixing solid | JSR CORPORATION (JP) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | SLC38A7, SLC7A1, SLC6A7 | KMT2A 2225/4885ALDH1A1 2442/4885HPGD 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.